Cooperative pricing rules extend under oversight

Summary#

HB 300, “Expiration of cooperative agreements; period of oversight by VDH Commissioner, transfer of records,” would amend Virginia law and add four sections on a hospital cooperative agreement governed by a 2017 order. Its stated goal is to set when that order’s conditions expire and how some pricing restrictions are supervised afterward. The supplied status says it passed the House of Delegates; that does not make it law.

  • The conditions in the Commissioner’s October 30, 2017, order would expire on the later of June 30, 2028, or the expiration of the certificate of public advantage governing the same agreement, issued by another state.
  • Pricing restrictions in effect at that expiration would continue for five years under the Commissioner’s active supervision. They could be changed during that period only by written agreement between the Commissioner and the entity subject to them.
  • Within 90 days before the conditions expire, the Commissioner and the entity must make an agreement about the restrictions. If they do not, the restrictions remain in effect until they agree on changes.
  • The entity must report compliance each year; the Commissioner must report each year to the Attorney General. The Attorney General’s authority under Virginia’s Antitrust Act would remain.
  • The Commissioner may seek reimbursement for reasonable, actual supervision costs and may impose a civil penalty of up to $50,000 per violation. The Department of Health must repeal specified regulations when the stated expiration trigger occurs.
  • Despite the bill’s title referring to transfer of records, the supplied operative text contains no records-transfer rule.

What it means for you#

  • The entity subject to the pricing restrictions: It would have to keep following them during the five-year supervision period, report compliance annually, and may have to reimburse supervision costs or pay penalties for violations. If it transfers substantially all its principal assets in Virginia and inpatient-care competition is not restored, responsibility for the restrictions would transfer with those assets.
  • The Commissioner and Department of Health: The Commissioner would supervise the restrictions, report to the Attorney General annually, and could hire experts whose costs may be reimbursed. The Department would collect reimbursements and penalties; reimbursement funds are restricted to supervision costs, while penalties must support specified regional health-improvement efforts.
  • Patients and the public: The bill does not directly set prices or guarantee that prices, services, or access to care will change. The existing cooperative agreement and pricing restrictions are not fully described in the supplied material, so their practical effect is unclear.

Money#

The bill allows supervision costs to be charged to the parties subject to the restrictions, but no cost estimate is provided.

  • Reimbursement is capped at $200,000 a year unless the Commissioner gives notice at least 90 days before the fiscal year ends that costs are expected to exceed that amount. The bill does not state a higher maximum.
  • The Commissioner must provide quarterly cost reports, and the supervised parties must pay within 30 days of a reimbursement request.
  • Civil penalties of up to $50,000 per violation would go to the Department of Health for specified regional health-improvement efforts.
  • No publicly available information on expected staffing, total costs, reimbursements, or penalty revenue is in the supplied material.

What is unclear#

  • The parent Code provisions and the existing regulations are not supplied, so the current law and how much of the bill is new could not be verified.
  • The bill does not identify the affected entity by name or explain the current restrictions in detail.
  • It is unclear how the five-year limit interacts with the rule that restrictions remain in place until the parties agree on changes if they do not reach an agreement before expiration.
  • The bill does not set out procedures for challenging a penalty or resolving disputes, or define how the Commissioner would decide a violation.
  • The timing of the other state’s certificate expiration could affect when the order’s conditions end. The bill also does not explain how the required agreement would work if that date changes.
  • The supplied text gives no records-transfer provision, despite the title’s reference to one.

Case for#

  • The bill appears intended to prevent pricing restrictions from ending abruptly when the order’s conditions expire.
  • Continued supervision and annual reports could give the state a way to monitor compliance during the transition.
  • Requiring the entity to pay reasonable, documented supervision costs could limit the expense borne by the Department of Health.
  • Transferring responsibility for restrictions with certain assets could help keep them attached to the relevant operations when ownership changes.

Case against#

  • One concern is that the restrictions may continue beyond the stated five years if no agreement is reached; the text does not clearly resolve that interaction.
  • The Commissioner would have substantial supervisory power, including the power to impose penalties, but the bill does not specify a process for disputes or appeals.
  • Costs could exceed $200,000 a year after notice, with no stated upper limit or estimate of likely costs.
  • The bill does not explain how continued pricing restrictions would affect patients, prices, or competition in practice.